

Doxorubicin 30mg/m² per day i.v. infusion over 30 min from day 1-3 and Cytosine Arabinoside 100mg/m² per day i.v. infusion over 16 hours from day 1-7. For FAB group M3, doxorubicin 30mg/m² per day i.v. infusion over 30 min was

given on days 1, 3, 5, 7 (4 doses) along with All Trans Retinoic Acid (ATRA) in a dose of 45mg/m² per oral daily in 2 divided doses from day 1 till remission⁽⁹⁾.




Fig. 2. Mutation sensitive digestion analysis (MSDA) from AML patients. PCR amplified DNA digested with BstNI for N-RAS codon 12 mutation. Lane 7, undigested control; lane 2, 3, 4 and 5 were wild N-RAS AML patients; Lanes 1 and 6 show AML cases with mutant N-RAS AML patents (116-bp band in lane 1, 6 was a result of N-RAS N12 mutation); lane 8, DNA size markers. Electrophoresis was done in 2% agarose gel containing ethidium bromide (final concentration 0.5 µg/ml) at (4V/cm) for 60 min.




Fig. 3. Mutation sensitive digestion analysis (MSDA) from AML patients. PCR amplified DNA digested with HphI for N-RAS codon 13 mutation. Lane 7, undigested control; lane 1, 2, 3, 4, 5 and 6 were wild N-RAS AML patients; Lane 8, DNA size markers. Electrophoresis was done in 2% agarose gel containing ethidium bromide (final concentration 0.5 µg/ml) at (4V/cm) for 60 min.